Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis

Summary

The Polish multicentre observational (non-interventional) study aiming to collect data on the management and clinical outcomes of patients with gMG that received ravulizumab.

Eligibility

Inclusion Criteria:

* Adult (aged ≥18 years) patients with gMG, naive to complement inhibitors, receiving ravulizumab treatment in the frames of NDP in Poland.
* Patients willing to participate in the study and signed Informed Consent Form (ICF).
* Vaccination against N. meningitidis

Exclusion Criteria:

* Those who plan to participate in gMG clinical trial on/after the date of first ravulizumab infusion through NDP.
* Cognitive incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.

Conditions2

Interventions1

Related trials

• Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis — Alexion Pharmaceuticals, Inc.
• A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab — Alexion Pharmaceuticals, Inc.
• Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders — Mayo Clinic

Browse More Trials